Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Florantyrone is a synthetic small molecule derivative of fluoranthene that functions as a hydrocholeretic agent. Developed by G.D. Searle & Co. and marketed under the brand name Zanchol, it was primarily indicated for the treatment of biliary tract disorders such as chronic cholecystitis and post-cholecystectomy syndrome. Unlike traditional choleretics that increase the secretion of bile salts, florantyrone stimulates the production of a high volume of watery bile with low solid content. This action helps to flush the biliary ducts and prevent bile stasis. The drug is currently considered obsolete and has been discontinued from most markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on florantyrone.